Fig. 7: Pharmacokinetics and biodistribution of T-AsiG-CPL in vivo.
From: Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine
a Fluorescence images of blood samples from the tumor-bearing mice treated with siG-Cy5, AsiG-Cy5, or T-AsiG-Cy5-CPL. b Pharmacokinetic curves of siG-Cy5, AsiG-Cy5, and T-AsiG-Cy5-CPL in the blood, shown as the percentage of the injected dose (% ID) (n = 3 mice). Ex vivo fluorescence images of tumors and major organs at 24 h (c) and 48 h (e) following i.v. administration of siG-Cy5, AsiG-Cy5 or T-AsiG-Cy5-CPL. The average fluorescence intensities in tumors and major organs at 24 h (d) and 48 h (f), (n = 3 mice). The mice were administered various fluorescent formulations (siG: 1.0 mg/kg; TPCA-1: 20 mg/kg) via tail vein injection. The data in (b, d, f) are presented as the mean ± SEM. Two-way ANOVA (d, f) with Bonferroni’s multiple comparisons test was used for statistical significance analysis. Source data are provided as a Source Data file.
